Cargando…
Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12–17 Years in the United States
As part of a phase 4, randomized, double-blind, placebo-controlled trial to assess the immunogenicity and safety of PXVX0200 in children and adolescents aged 2–17 years, a subset of 73 adolescent subjects aged 12–17 years was followed for 2 years after vaccination and had blood collected for antibod...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Tropical Medicine and Hygiene
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103473/ https://www.ncbi.nlm.nih.gov/pubmed/33819178 http://dx.doi.org/10.4269/ajtmh.20-1576 |
_version_ | 1783689314515812352 |
---|---|
author | McCarty, James M. Cassie, David Bedell, Lisa Lock, Michael D. Bennett, Sean |
author_facet | McCarty, James M. Cassie, David Bedell, Lisa Lock, Michael D. Bennett, Sean |
author_sort | McCarty, James M. |
collection | PubMed |
description | As part of a phase 4, randomized, double-blind, placebo-controlled trial to assess the immunogenicity and safety of PXVX0200 in children and adolescents aged 2–17 years, a subset of 73 adolescent subjects aged 12–17 years was followed for 2 years after vaccination and had blood collected for antibody assays on days 1, 11, 29, 91, 181, 365, 547, and 730. Endpoints included serum vibriocidal antibody (SVA) seroconversion, defined as a 4-fold or greater rise in antibody titer over baseline; geometric mean titers (GMTs); and geometric mean fold increase (GMFI) over baseline. Serum vibriocidal antibody seroconversion persisted in most subjects, with a rate of 64.5% noted at day 730. Geometric mean titers and GMFI both peaked at day 11 and remained greater than baseline at all time points, including day 730. Vaccination with PXVX0200 produces an immune response which persists for at least 2 years in adolescents aged 12–17 years. |
format | Online Article Text |
id | pubmed-8103473 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The American Society of Tropical Medicine and Hygiene |
record_format | MEDLINE/PubMed |
spelling | pubmed-81034732021-05-10 Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12–17 Years in the United States McCarty, James M. Cassie, David Bedell, Lisa Lock, Michael D. Bennett, Sean Am J Trop Med Hyg Articles As part of a phase 4, randomized, double-blind, placebo-controlled trial to assess the immunogenicity and safety of PXVX0200 in children and adolescents aged 2–17 years, a subset of 73 adolescent subjects aged 12–17 years was followed for 2 years after vaccination and had blood collected for antibody assays on days 1, 11, 29, 91, 181, 365, 547, and 730. Endpoints included serum vibriocidal antibody (SVA) seroconversion, defined as a 4-fold or greater rise in antibody titer over baseline; geometric mean titers (GMTs); and geometric mean fold increase (GMFI) over baseline. Serum vibriocidal antibody seroconversion persisted in most subjects, with a rate of 64.5% noted at day 730. Geometric mean titers and GMFI both peaked at day 11 and remained greater than baseline at all time points, including day 730. Vaccination with PXVX0200 produces an immune response which persists for at least 2 years in adolescents aged 12–17 years. The American Society of Tropical Medicine and Hygiene 2021-05 2021-04-05 /pmc/articles/PMC8103473/ /pubmed/33819178 http://dx.doi.org/10.4269/ajtmh.20-1576 Text en © The American Society of Tropical Medicine and Hygiene https://creativecommons.org/licenses/by-nc/4.0/Open Access statement. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and reproduction in any medium for non-commercial purposes, provided the original author and source are credited, a link to the CC License is provided, and changes – if any – are indicated. |
spellingShingle | Articles McCarty, James M. Cassie, David Bedell, Lisa Lock, Michael D. Bennett, Sean Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12–17 Years in the United States |
title | Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12–17 Years in the United States |
title_full | Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12–17 Years in the United States |
title_fullStr | Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12–17 Years in the United States |
title_full_unstemmed | Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12–17 Years in the United States |
title_short | Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12–17 Years in the United States |
title_sort | long-term immunogenicity of live oral cholera vaccine cvd 103-hgr in adolescents aged 12–17 years in the united states |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103473/ https://www.ncbi.nlm.nih.gov/pubmed/33819178 http://dx.doi.org/10.4269/ajtmh.20-1576 |
work_keys_str_mv | AT mccartyjamesm longtermimmunogenicityofliveoralcholeravaccinecvd103hgrinadolescentsaged1217yearsintheunitedstates AT cassiedavid longtermimmunogenicityofliveoralcholeravaccinecvd103hgrinadolescentsaged1217yearsintheunitedstates AT bedelllisa longtermimmunogenicityofliveoralcholeravaccinecvd103hgrinadolescentsaged1217yearsintheunitedstates AT lockmichaeld longtermimmunogenicityofliveoralcholeravaccinecvd103hgrinadolescentsaged1217yearsintheunitedstates AT bennettsean longtermimmunogenicityofliveoralcholeravaccinecvd103hgrinadolescentsaged1217yearsintheunitedstates |